Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

AbbVie

Gilead Sciences

Teva Pharmaceutical

The WHO's Solidarity testing project could be good news for the world.

COVID-19 Claiming Lives But Therapeutics Could Be on the Way

Novartis (NVS) announces pipeline updates on inclisiran and regulatory updates on Cosentyx and Zolgensma.

Novartis Reports Data on Inclisiran, CHMP Positive on Zolgensma

Abbott Labs

Johnson & Johnson

Regeneron Pharmaceuticals

Sanofi

Measures currently being taken against COVID-19 are the only means of containing and suppressing the virus.

Big Pharma Advances on COVID-19

Amgen

Biogen

Bristol-Myers

iShares Nasdaq Biotechnology ETF

Pfizer

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Drug developers took center stage as the world looks to these companies to deliver an answer to COVID-19.

4 Reasons Drug Stocks Are a Buy Right Now

Pipeline and products at these three pharmaceutical companies mean long-term revenue growth once current market turmoil has passed.

My Top 3 Drug Stocks to Buy in the Market Crash

The world is progressing towards a vaccine for the coronavirus with multiple large-scale and properly controlled studies exploring the efficacy of hydroxychloroquine, Novartis AG (NYSE: NVS) CEO Vas Narasimhan said on CNBC.

Novartis CEO Talks Coronavirus Vaccine Progress, Timeline

Inovio Pharmaceuticals

Moderna

Mylan

An old malaria drug may unseat newer investigational coronavirus treatments -- if data is confirmed.

3 Things to Know if Chloroquine Wins the COVID-19 Treatment Race

The CEO of Novartis has said it is "too soon" to know whether two anti-malaria drugs could be the definitive vaccine for the coronavirus.

Swiss pharma giant says it's 'too soon' to know whether malaria drug could be coronavirus vaccine

Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.

Novartis to Donate Generic Hydroxychloroquine for Coronavirus

Amneal Pharmaceuticals

Bayer AG

No, but doctors can still use the drugs despite limited evidence of their effectiveness.

Are Chloroquine and Hydrochloroquine Approved to Treat COVID-19?

Allied Healthcare Products

GenMark Diagnostics

Hepion Pharmaceuticals Inc

The coronavirus pandemic has delivered a shock to our economy, and the severity will be dependent on whether the "curve is flattened".

Coronavirus Pandemic Requires Patient Investing And A Focused Portfolio

Novartis will donate enough doses of malaria drug hydroxychloroquine to treat several million patients in the fight against the coronavirus, if it wins approval, the Swiss company said on Friday.

Novartis to donate malaria drug in fight against coronavirus

Pharmaceutical giant Novartis AG's (NYSE: NVS) subsidiary Sandoz Inc. has agreed to pay $195 million in penalties to avoid facing criminal charges in a price-fixing case, the Justice Department announced Monday.

Novartis' Sandoz To Pay $195M For Price-Fixing

The company admits it was guilty of fixing prices for a number of different products.

Novartis Subsidiary Agrees to Pay $195 Million Over Price-Fixing Charges

The Justice Department says pharmaceutical company Sandoz will pay a $195 million penalty to resolve criminal charges of conspiring to fix prices and rig bids for generic drugs.

Novartis subsidiary Sandoz to pay $195 million over antitrust allegations

Novartis unit Sandoz has agreed to pay $195 million to reach a deferred prosecution agreement aimed at resolving antitrust charges, the Justice Department said on Monday.

Novartis unit Sandoz agrees to pay $195 million to resolve antitrust charges

Kellogg

Children's Place

The following long-term dividend payers outperform the S&P 500 Index significantly in terms of a higher dividend yield.

A Trio of High-Yield Payers for Dividend Investors

Disney

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Exxon Mobil

These blue-chip names are stocks to sell now as the coronavirus continues its rapid spread around the world.

These 4 Stocks to Sell Are Melting Down Now

A pair of phase 3 trials offer strong evidence that ofatumumab is more effective than Sanofi's Aubagio.

U.S. and EU Regulators Reviewing Novartis' Leukemia Drug for Expanded Approval in Multiple Sclerosis

GlaxoSmithKline

Approvals were down slightly year over year.

FDA Approved 1,014 Generic Drugs in 2019

Incyte

The Food and Drug Administration will expedite its review of capmatinib.

Potential Lung Cancer Drug from Incyte and Novartis to Get a Priority Review from FDA

AstraZeneca

Eli Lilly

For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings.

5 Big Dividend Pharmaceutical Stocks to Buy as Health Care Could Explode Higher

LONDON and REDWOOD CITY, Calif., Feb.  10, 2020  (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a $5 million convertible equity financing with Novartis Pharma (AG) (“Novartis”) and concurrently entered into a Securities Purchase Agreement to issue up to $28 million of the Company’s ordinary shares exchangeable for American Depositary Shares (“ADSs”), including a $3 million initial purchase, with Aspire Capital Fund, LLC (“Aspire Capital”), a Chicago-based institutional investor. Proceeds from these transactions are intended to be used by Mereo for general corporate purposes, including clinical trial activity and working capital.

Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million

We examine three biotech companies' past performances and future outlooks.

3 Biotech Companies Analyzed

Bertrand Bodson, chief digital officer of Novartis, in conversation with Stephanie Mehta at the 2020 World Economic Forum in Davos, Switzerland. 

		 
			 
		
			if(typeof(jQuery)=="function"){(function($){$.fn.fitVids=function(){}})(jQuery)};
				jwplayer('jwplayer_pi0Enztb_G2hQKLvX_div').setup(
				{"playlist":"https:\/\/content.jwplatform.com\/feeds\/pi0Enztb.json","ph":2}
			);
		
	
Bertrand Bodson, chief digital officer of Novartis, in conversation with Stephanie Mehta at the 2020 World Economic Forum in Davos, Switzerland.

Video: Novartis’s chief digital officer on how the company is becoming un-bossed

News for Novartis Stock (NVS)